Store in original package until time of use. Argatroban: Discard product if it contains particulate matter, is cloudy, or discolored – Do not freeze – Protect from . Baxter U.S. – Healthcare Professionals – ARGATROBAN Injection in % Sodium Chloride mg/ mL (1 mg/1 mL). Argatroban is approved by the US Food and Drug Administration .. 51 to minutes), package insert recommendations provide guidance on.

Author: Gardarr Kajikazahn
Country: Kosovo
Language: English (Spanish)
Genre: Photos
Published (Last): 24 September 2011
Pages: 417
PDF File Size: 16.28 Mb
ePub File Size: 10.5 Mb
ISBN: 962-7-27475-348-2
Downloads: 34854
Price: Free* [*Free Regsitration Required]
Uploader: Malajinn

Major An additive risk of bleeding may be seen in patients receiving dalteparin in combination with other anticoagulants. Additive hematological argatrovan are possible as a result of the platelet inhibitory effects of sulfinpyrazone; the sulfide metabolite of sulfinpyrazone appears responsible for this effect.

Moderate Due to the thrombocytopenic effects of antineoplastic agents, an additive risk of bleeding may be seen in patients receiving concomitant anticoagulants.

Major Monitor patients closely and promptly evaluate any signs or symptoms of bleeding if apixaban and other anticoagulants are used concomitantly. The target ACT range is seconds measured using the Haemotec device. During the 30 day study period thrombotic events occurred during argatroban administration in two patients and following argatroban discontinuation in three other patients.

However, this is unlikely to be of clinical relevance in patients receiving Exembol Multidose. Alternative uricosuric agents may be considered.

PDR Search

The patient denied noncompliance and other changes in diet, medications, or health. For conversion to oral anticoagulant therapy in patients receiving argatroban. Total body clearance is approximately 5. As the authors suggest, argatroban should be initiated at a dose of 0. Argatroban is a suitable regimen for use in renal replacement therapy RRTdue to the fact that it is mainly eliminated via the liver, and moreover dialytic clearance by high-flux membranes is considered clinically insignificant.

There was also no difference in INRs found between groups. During one of the available, published clinical trials in patients with osteoarthritis, those patients with bleeding disorders or using anticoagulants or antiplatelets were excluded from enrollment.


In a Quick type PT assay the recommendations below should be considered: Steady-state anticoagulant effects are well correlated with steady-state plasma concentrations. No initial dose regimen adjustment with respect to renal function is necessary.

Theoretically, the risk of bleeding argstroban be increased, but some studies that combined omega-3 fatty acids and anticoagulant agents did not produce clinically significant bleeding events.

Solutions are physically and chemically stable for up to 96 hours when protected from light and stored at controlled room temperature of 20 to 25 degrees C 68 to 77 degrees F or under refrigeration at 2 to 8 degrees C 36 to 46 degrees F.

The patient stopped taking the inseert but continued taking the aspirin with no recurrence of bleeding over a 3-month period.

For patients with moderate hepatic impairment Child-Pugh Class Ban initial dose of 0. No specific antidote to Exembol Multidose is available. Moderate Drugs that can cause thrombocytopenia, such as antithymocyte globulin, may lead to an increased risk of bleeding when given concurrently with anticoagulants.

Toxicity studies with continuous intravenous infusions and reproduction toxicity studies using daily intravenous bolus injections achieved only limited systemic exposure to argatroban 2 times the exposure seen in humans. Consider the developmental and health benefits of breast-feeding along with the mother’s clinical need for argatroban and any potential adverse effects on the breast-fed infant from argatroban or the underlying maternal condition. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.

The INR should be closely monitored during concurrent therapy with warfarin, particularly during the initiation or termination phases of sulfinpyrazone treatment. Elimination On termination of the infusion, the concentration of argatroban decreased rapidly. Javascript is currently disabled in your browser.

Respiratory,thoracic and mediastinal disorders. Infusions of argatroban should be gradually tapered in patients with unstable angina following initiation of aspirin or other antiplatelet agents.


If possible, intramuscular injections should be avoided in patients receiving argatroban. Most patients required multiple dose adjustments to maintain anticoagulation parameters within the desired range. This medicinal product contains sorbitol.

Exembol Multidose 100 mg/ml concentrate for solution for infusion

Solutions srgatroban physically and chemically stable for up to 96 hours when protected from light and stored at room temperature, 20 to 25 degrees C 68 to 77 degreed F or in the refrigerator, 2 to 8 degrees C 36 to 46 degrees F.

Data on the use of high-dose argatroban e. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. In regard to warfarin, published data are limited to a random case report; however, the product labeling for warfarin includes garlic as having potential for interaction due inserh additive pharmacologic activity. The symptoms of acute toxicity were loss of righting reflex, tremors, clonic convulsions, paralysis of hind limbs, and coma.

The procedure may proceed if the ACT is greater than sec. Minor Drugs that decrease clotting, such as anticoagulants, could decrease the efficacy of photodynamic therapy.

[Full text] Update on argatroban for the prophylaxis and treatment of heparin-indu | JBM

Argatroban has a relatively short elimination half-life of approximately 45 minutes, which is predominantly performed via hepatic metabolism. Kava Kava, Piper methysticum: Moderate Icosapent ethyl is an ethyl ester of the omega-3 fatty acid eicosapentaenoic acid EPA. Because omega-3 fatty acids inhibit platelet aggregation, caution is advised when icosapent ethyl is used concurrently with anticoagulants, platelet inhibitors, or thrombolytic agents.

If switching from another anticoagulant to apixaban, discontinue the other anticoagulant and start apixaban at the usual time of the next dose of the other anticoagulant.

Author: admin